adagrasib
mirati
['sclc', 'nsclc', 'adagrasib']
adagrasib produced responses in 43% of previously treated patients with nsclc containing a krasg12c mutation, with median overall survival of 12.6 months. #asco22 
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.